Nilanjan Ghosh shares phase 1b trial findings showing high response rates with lisocabtagene maraleucel, a CD19-directed chimeric antigen receptor T-cell agent, as second-line therapy in patients with aggressive, relapsed or refractory, large B-cell non-Hodgkin lymphomas who were ineligible for haematopoietic stem cell transplantation (6:46).